Abstract
Local recurrence accounts for >90% at the time of relapse in high grade glioma (HGG). Anti-angiogenic therapy with Bevacizumab has recently shown impressive radiological and clinical responses in HGG. It is not clear if the responses translate into a change in pattern of recurrence following therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
